louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT00962793: Diagnosis of Latent Tuberculosis(TB) Infection in Health Care Workers Using TST and Whole Blood Interferon-γ Assay
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Tuberculosis
Keywords: latent tuberculosis prevalence of health care workers
Lead sponsor: Yonsei University
Sponsor class: OTHER
First posted: 2009-08-20
Sex: ALL
Minimum age (years): 20
Standard ages: ADULT
OLDER_ADULT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: latent tuberculosis prevalence of health care workers

Brief summary: The investigators think that the health care workers who contact frequently with active tuberculosis patients have more increased prevalence of LTBI compared with those who don't.


Eligibility criteria: Inclusion Criteria:

* health care workers

Exclusion Criteria:

* active pulmonary tuberculosis
* previous Tuberculosis history
* below 20 years old
* history of hypersensitivity about PPD
* pregnant

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT01373593: Ultrasound Guided Blocks of the Iliohypogastric and Ilioinguinal Nerves in Persistent Postherniorrhaphy Pain Patients
Official title: Ultrasound Guided Blocks of the Iliohypogastric and Ilioinguinal Nerves in Persistent Postherniorrhaphy Pain Patients
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE4
Conditions: Pain
Keywords: persistent postherniorrhaphy pain
Lead sponsor: Rigshospitalet, Denmark
Sponsor class: OTHER
First posted: 2011-06-15
Enrollment: 12
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: DIAGNOSTIC

Brief summary: In this controlled study the investigators will examine the analgesic and sensory effects of ultrasound-guided blocks of the iliohypogastric and ilioinguinal nerves with lidocaine in persistent postherniorrhaphy pain patients.


Eligibility criteria: Inclusion Criteria:

* patients older than 18 years with severe postherniorrhaphy pain (numerical rating scale \[NRS\] \> 6) for more than 6 month

Exclusion Criteria:

* known amide local anesthetic drug allergy
* recurrent hernia

Primary outcomes:
measure: changes (lidocaine vs. placebo) in pain perception, sensory mapping and QST compared to pre-block values.
timeFrame: 20 minutes after the block
Secondary outcomes:
Other outcomes:
Locations:
city: Copenhagen
country: Denmark
facility: Rigshospitalet
Study officials:
References:
citation: Bischoff JM, Koscielniak-Nielsen ZJ, Kehlet H, Werner MU. Ultrasound-guided ilioinguinal/iliohypogastric nerve blocks for persistent inguinal postherniorrhaphy pain: a randomized, double-blind, placebo-controlled, crossover trial. Anesth Analg. 2012 Jun;114(6):1323-9. doi: 10.1213/ANE.0b013e31824d6168. Epub 2012 Mar 30.
Clinical trial NCT05576493: Combined Phacoemulsification and Diode Laser Therapy in Chronic Angle Closure Glaucoma
Official title: Combined Phacoemulsification and Different Modes of Diode Laser Therapy in Management of Chronic Angle Closure Glaucoma. A Comparative Study
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: NA
Conditions: Angle Closure Glaucoma
Keywords: angle closure glaucoma
cyclophotocoagulation
Lead sponsor: Cairo University
Sponsor class: OTHER
First posted: 2022-10-12
Enrollment: 88
Sex: ALL
Minimum age (years): 20
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: comparing different types of cuclophotocoagulation with cataract extraction to cataract extraction and goniocynechiolysis in cases of chronic angle closure glaucoma

Detailed description: Evaluation of the safety of MP-TSCPC , CW-TSCPC and endoscopic cyclophotocoagulation when combined with phacoemulsification in cases with CACG Comparing the efficacy of the combined procedures in control of the IOP and the success rate versus lens extraction combined with synechiolysis

Eligibility criteria: Inclusion Criteria:

* Patients between 20 to 70 years

chronic angle closure glaucoma

Exclusion Criteria:

* Patients in acute attack of angle closure.
* Patients with previous filtering surgery or cycloablative procedure

Primary outcomes:
measure: the percentage of intraocular pressure change
timeFrame: 6 Months
Secondary outcomes:
measure: percent change of antiglaucoma medications
timeFrame: 6 Months
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: Kasr Alainy
Study officials:
affiliation: kasr alainy
name: Ahmed Abdelrahman, PhD
role: STUDY_CHAIR
References:
Clinical trial NCT00600093: Perioperative Treatment of Parkinsonian Patients With Parenteral Amantadine
Official title: Perioperative Treatment of Parkinsonian Patients With Parenteral Amantadine
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE2
Conditions: Parkinson Disease
Perioperative Care
Keywords: Amantadine
Lead sponsor: Rabin Medical Center
Sponsor class: OTHER
First posted: 2008-01-24
Enrollment: 20
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine whether administrating of Amantadine (a dopamine agonist) to patients suffering from Parkinson disease during the perioperative period is safe, and to asses potential benefits of this treatment.


Eligibility criteria: Inclusion Criteria:

* Patient with a diagnosis of Parkinson Disease refered for surgery at our institution.

Exclusion Criteria:

* Cardiac and neurosurgical procedures
* Inability to sign informed Consent
* allergy to Amantadine
* Congestive heart failure
* Arrythmia (including bradycardia below 55 bpm)
* renal failure (creatinin above 1.5)
* If a patient will develop agitation or delirium lasting longer then 8 hours he will not receive the second dose of amantadine.

Primary outcomes:
measure: Mortality, Surgical site infection, Pneumonia, Myocardial Infarction, Cerebral Vascular Accident (CVA).
timeFrame: 28 days
Secondary outcomes:
measure: UPDRS score
timeFrame: 2,28 days
measure: Pain (vas score), Analgetic drugs requirement
timeFrame: 2 days
Other outcomes:
Locations:
city: Petah Tikva
country: Israel
facility: Rabin Medical Center
Study officials:
affiliation: Rabin Medical Center
name: Aeyal Raz, MD,PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Raz A, Lev N, Orbach-Zinger S, Djaldetti R. Safety of perioperative treatment with intravenous amantadine in patients with Parkinson disease. Clin Neuropharmacol. 2013 Sep-Oct;36(5):166-9. doi: 10.1097/WNF.0b013e31829bd066.
Clinical trial NCT03952793: Organoids From Metastases of Prostate Cancer
Official title: Development of the Organoids Technique From Metastases From Patients With Advanced Form of Prostate Cancer: Use in Basic Research
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: NA
Conditions: Prostatic Neoplasm
Lead sponsor: Centre Antoine Lacassagne
Sponsor class: OTHER
Collaborators: name: Centre Méditerranéen de Médecine Moléculaire UMR_S-1065
First posted: 2019-05-16
Enrollment: 1
Sex: MALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: BASIC_SCIENCE

Brief summary: The aim of the study is the development of the organoid culture technique from metastases from patients with advanced form of prostate cancer. Once the technique is set up, the organoid will serve to test several antitumor molecules.


Eligibility criteria: Inclusion Criteria:

* Patient with metastatic prostate cancer
* Patient having a biopsy programmed as part of his care.
* Patient having a biopsy programmed as part of hiscare.
* Patient with sufficient tumor volume after imaging data review by the radiologist to guarantee a sufficient quantity of material for the diagnosis of biopsy and additional material for the study.
* INR \<1.5; Platelets \> 50000 / μL

Exclusion Criteria:

* Patient under age of 18 years.
* Patient under Plavix or Effient or Ticlid without possibility of suspension for 5 days, low molecular weight heparin without possibility of suspension of the dose before the intervention, or Fondaparinux without possibility of suspension, or ReoPro without possibility of suspension for 24h and aPTT \<50s and ACT \<150s, or Integrilin or Aggrastat or Argatroban without possibility of suspension 4 H before the intervention, or Angiomax without possibility of suspending 2H to 3H if CrCL\> 50 mL / min or 3H to 5h if CrCL \<50 mL / min before the intervention or and Pradaxa without possibility of suspension 2 to 3 days if CrCL\> 50 mL / min or 3 to 5 days if CrCL \<50 mL / min before the procedure
* Patient under desmopressin acetate (DDAVP)
* Patient with HIV or Hepatitis C positive or Hepatitis B infection, defined by either a detection of the HBs antigen or the presence of anti HBc antibodies without HBs antibody detectable.

Primary outcomes:
measure: Success rate of establishment of the organoid culture
timeFrame: 15 days
Secondary outcomes:
measure: Drugs testing on organoid for cell viability
timeFrame: 20 days
measure: Cell Apoptosis Molecular and cellular mechanisms of drugs responses
timeFrame: 20 days
measure: Cell proliferation Molecular and cellular on mechanisms of drugs responses
timeFrame: 20 days
Other outcomes:
Locations:
city: Nice
country: France
facility: Centre Antoine Lacassagne
Study officials:
References:
Clinical trial NCT01967693: Characterization of Laryngeal Contact Granulomas: Retrospective Analysis of Symptoms, Promotive Factors and Therapy
Official title: Characterization of Laryngeal Contact Granulomas: Retrospective Analysis of Symptoms, Promotive Factors and Therapy
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Laryngeal Contact Granuloma
Keywords: Laryngeal contact granuloma
Treatment type
Outcome
Lead sponsor: University of Zurich
Sponsor class: OTHER
First posted: 2013-10-23
Enrollment: 42
Sex: ALL
Minimum age (years): 18
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Former patients with laryngeal contact granuloma who were treated in this hospital.

Brief summary: Retrospective analysis of data from patients with laryngeal contact granulomas in order to identify possible differences and/or similarities between the cases and in order to determine whether and which conclusions can be drawn on disease and therapy.

Detailed description: This is a retrospective analysis of data from patients with laryngeal contact granulomas in order to identify possible differences and/or similarities between the cases and in order to determine whether and which conclusions can be drawn on disease and therapy.

Eligibility criteria: Inclusion criteria:

Laryngeal contact granuloma in adults with documentation of symptoms, possible causes, therapy and outcome

Exclusion criteria:

Incomplete information on the diagnosis laryngeal contact granuloma (symptoms, promotive factors, findings)

Primary outcomes:
measure: Percentage of patients with similar therapy outcome as a measure of therapy predictability
timeFrame: 4 to 6 months after finishing the therapy
Secondary outcomes:
Other outcomes:
Locations:
city: Zurich
country: Switzerland
facility: University Hospital Zurich, Division of Otorhinolaryngology
state: ZH
Study officials:
affiliation: University Hospital Zurich, Division of Otorhinolaryngology
name: Jörg E. Bohlender, KD Dr. med.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03226093: Safety Analysis of Implantation of Stromal Vascular Fraction
Official title: Safety Analysis of Implantation of Stromal Vascular Fraction
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Safety Issues
Lead sponsor: Bioheart, Inc.
Sponsor class: INDUSTRY
First posted: 2017-07-21
Enrollment: 676
Sex: ALL
Minimum age (years): 15
Maximum age (years): 97
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Stromal vascular fraction (SVF) can be isolated from fat (adipose) tissue in an outpatient in-clinic procedure. Platelet rich plasma (PRP) can be isolated from peripheral blood. The SVF includes a variety of different cells and growth factors where the adipocyte (fat cell) population has been removed. The use of SVF in the clinic for a variety of indications is analyzed for incidences of safety and tolerability.


Eligibility criteria: Inclusion Criteria:

* Age between 15 and 97
* Able and willing to give written informed consent
* Up to date on all age and gender appropriate cancer screening

Exclusion Criteria:

* Females who are pregnant or nursing or females of childbearing potential who are unwilling to maintain contraceptive therapy for the duration of the study
* Life expectancy \< 6 months due to concomitant illnesses.
* Exposure to any investigational drug or procedure within 1 month prior to study entry or enrolled in a concurrent study that may confound results of this study.
* Active infectious disease patients known to have tested positive for HTLV, HBV, HCV, CMV (IgM \> IgG) and/or syphilis. Will have an expert consulted as to patient eligibility based on the patient's infectious status
* Any illness which, in the Investigator's judgment, will interfere with the patient's ability to comply with the protocol, compromise patient safety, or interfere with the interpretation of the study results

Primary outcomes:
measure: Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]
timeFrame: 12 months
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT04722211: Effects of Lactobacillus Plantarum PS128 on the Parkinsonian Symptoms in Parkinson's Disease.
Official title: Effects of Lactobacillus Plantarum PS128 on the Parkinsonian Symptoms in Parkinson's Disease.
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Parkinson Disease
Keywords: probiotics, parkinson's disease
Lead sponsor: Professor Lu Neurological Clinic
Sponsor class: OTHER
First posted: 2021-01-25
Enrollment: 120
Sex: ALL
Minimum age (years): 45
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: 120 Participants are assigned to the PS128 and a placebo group, under the double-blind trial.
Primary purpose: TREATMENT

Brief summary: This RCT study is designed to examine the extent to which L. plantarum PS128 can improve symptoms in PD patients. L. plantarum PS128 is a psychobiotic that regulates the level of dopamine in specific brain regions. Patients with PD will receive PS128 or placebo intervention for 12 weeks. Symptoms of PD will be clinically evaluated before and after the treatment, and the results will be compared.

Detailed description: This RCT study is designed to examine the extent to which L. plantarum PS128 can improve symptoms in PD patients. L. plantarum PS128 is a psychobiotic that regulates the level of dopamine in specific brain regions. Patients with PD will receive PS128 or placebo intervention for 12 weeks. Symptoms of PD will be clinically evaluated before and after the treatment, and the results will be compared.

Eligibility criteria: Inclusion Criteria:

* Modified Hoehn \&Yahr stage, MHY 1-3
* 45-80 years old
* at least 9 years education

Exclusion Criteria:

* Patients on antibiotics within the preceding one month
* Patients using of other probiotic products (sachet, capsule or tablet) within the preceding two weeks
* Have undergone surgery of liver, bladder, or gastrointestinal tract
* Have current or history of inflammatory bowel disease
* Have history of cancer
* Known allergy to probiotics
* Patients with comorbid dementia (Mini-Mental State Examination score ≤ 26) or major depression (The Beck Depression Inventory-II score ≥ 29)
* Have received deep brain stimulation
* Patients receiving artificial enteral or intravenous nutrition
* Diagnosed before 40 years old
* Poor control of other chronic diseases
* Not eligible judged by PI

Primary outcomes:
measure: UPDRS III
timeFrame: 12 weeks
measure: MHY
timeFrame: 12 weeks
measure: TUG
timeFrame: 12 weeks
Secondary outcomes:
measure: UPDRS I-IV
timeFrame: Baseline and Post-12 weeks
measure: SCL-90-R
timeFrame: Baseline and Post-12 weeks
measure: CPSQI
timeFrame: Baseline and Post-12 weeks
measure: VAS-GI
timeFrame: Baseline and Post-12 weeks
measure: PGIC
timeFrame: Post-12 weeks
Other outcomes:
Locations:
city: Taoyuan City
country: Taiwan
facility: Professor Lu Neurological Clinic
state: Guishan Dist.
Study officials:
References:
Clinical trial NCT06472011: Effects of Common Meals on Appetite and Satiety
Official title: Back to the Basics: Metabolic and Appetitive Characteristics of Meals
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Healthy
Lead sponsor: San Diego State University
Sponsor class: OTHER
First posted: 2024-06-24
Enrollment: 20
Sex: ALL
Minimum age (years): 18
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Intervention model description: 7 crossover arms for each subject
Primary purpose: OTHER

Brief summary: The objectives of this study are to assess the impacts of meals composed of lean steak and potatoes (with a small portion of broccoli) in comparison to other common entrée/starch food combinations on metabolic and appetite responses.

Detailed description: The objectives of this study are to utilize a novel, ecologically sound approach to assess the acute impacts of meals composed of lean steak and potatoes to other common entrée/starch food/vegetable combinations on metabolic and appetitive responses. Appetitive responses will serve as the primary outcome. Combinations for comparison will include lentil and sweet potato chili, macaroni and cheese, fish tacos, chicken and pea fried rice, pita and hummus, and creamy pork pasta.

Eligibility criteria: Inclusion Criteria:

* ages of 18-50 years
* BMI between 18-26

Exclusion Criteria:

* special dietary needs (e.g., gluten-free, etc.),
* 5% weight change in the previous 2 months,
* smoking, and substance use.

Primary outcomes:
measure: appetite response
timeFrame: baseline (B), 15 minutes from B, 30 minutes from B, 45 minutes from B, 60 minutes from B, 90 minutes from B, 120 minutes from B, 150 minutes from B, 180 minutes from B, 210 minutes from B, 240 minutes from B
Secondary outcomes:
measure: blood glucose
timeFrame: baseline (B), 15 minutes from B, 30 minutes from B, 45 minutes from B, 60 minutes from B, 90 minutes from B, 120 minutes from B, 150 minutes from B, 180 minutes from B, 210 minutes from B, 240 minutes from B
Other outcomes:
Locations:
city: San Diego
country: United States
facility: San Diego State University
state: California
Study officials:
References:
Clinical trial NCT03726411: The Effect of Non-surgical Periodontal Therapy on the Gingival Crevicular Fluid Levels of Prolactin Hormone in Patients With Periodontitis.
Official title: The Effect of Non-surgical Periodontal Therapy on the Gingival Crevicular Fluid Levels of Prolactin Hormone in Patients With Periodontitis.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Periodontitis
Prolactin in GCF
Keywords: periodontitis
Prolactin
GCF
non-surgical periodontal treatment
Lead sponsor: Cairo University
Sponsor class: OTHER
First posted: 2018-10-31
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: OTHER

Brief summary: The present study will be conducted on fifty participants. All participants will receive a full-mouth clinical examination, and the following periodontal parameters will be recorded: Plaque Index (PI). Gingival Index (GI), probing depth (PD), and clinical attachment level (CAL). All of these measurements will be recorded at six sites at baseline for all participants and 3 months after non-surgical periodontal therapy for the study group. GCF samples will be collected from the buccal aspects of teeth that had the highest signs of inflammation and attachment loss for periodontitis group at baseline and 3 months after non-surgical periodontal therapy. As for controls, the samples will be collected from buccal aspect of upper first molar at baseline. The samples will be assayed for prolactin by using an enzyme linked immunosorbent assay kits (Elisa) according to the manufacturer instruction.


Eligibility criteria: Inclusion Criteria:

* Subjects with moderate to severe chronic periodontitis, with probing pocket depth (PPD) ≥ 4-6 mm and clinical attachment level ≥ 4-5 mm, according to the American Academy of Periodontology.7
* Highly motivated and cooperative patients

Exclusion Criteria:

* The presence of any systemic disease.
* Taking medications for the last 3 months before conducting this study.
* Pregnancy and lactation.
* Any type of previous periodontal treatment (surgical or non-surgical) in the preceding 6 months.
* Smoking (former or current).

Primary outcomes:
measure: prolactin in GCF
timeFrame: 3 months
Secondary outcomes:
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: Faculty of Dentistry
Study officials:
References:
Clinical trial NCT01944111: Plicated Laparoscopic Adjustable Gastric Banding Study
Official title: Prospective Clinical Trial of Plicated Laparoscopic Adjustable Gastric Banding
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE1
Conditions: Weight Loss
Keywords: Gastric plication
Lead sponsor: Tenet Healthcare Corporation
Sponsor class: OTHER
First posted: 2013-09-17
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Compare plicated laparoscopic adjustable gastric banding to standard laparoscopic adjustable gastric banding in prospective clinical trial.

Detailed description: This is a prospective clinical trial comparing experimental plicated adjustable gastric banding versus standard adjustable gastric banding. All enrolled patients will choose to either standard (control group) banding or plication (study group) banding. Each patient will complete a standardized survey rating their satisfaction from surgery, their satiety levels and Green Zone Patient Questionnaire at each visit.

Eligibility criteria: Inclusion Criteria:

* Age older than 18 years
* Morbidly Obese
* BMI \>40 or
* BMI \>35 plus co-morbid obesity related disease conditions
* Without contraindications to bariatric surgery: eg pregnancy, desire to become pregnant within the next 12 months, myocardial infarct within the last 6 months, cancer within last 5 years, end stage renal/liver disease
* Without any metabolic or medically correctable causes for obesity: eg untreated hypothyroidism, Prader-Willi

Exclusion Criteria:

* Any patient not meeting the inclusion criteria
* Patients with any major medical problems contraindicating surgery
* Patients with a medically treatable cause of obesity
* Patients who elect to undergo a surgery other than Plication adjustable gastric banding or standard adjustable gastric banding
* Alcohol or drug addiction
* Established infection anywhere in the body at the time of surgery
* Previous history of bariatric surgery, intestinal obstruction, or adhesive peritonitis
* Family or patient history of autoimmune disease

Primary outcomes:
measure: Weight loss
timeFrame: at least 1 year
Secondary outcomes:
Other outcomes:
Locations:
city: St. Louis
country: United States
facility: Des Peres Hospital
state: Missouri
Study officials:
affiliation: Tenet Healthcare Corporation
name: James S Scott, MD
role: PRINCIPAL_INVESTIGATOR
References: